Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 377.55
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Sakar Healthcare Limited research, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant,...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITD
Data is available to registered users only
Buy
Sell